(NASDAQ: RPTX) Repare Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.
Repare Therapeutics's earnings in 2025 is -$127,894,000.On average, 2 Wall Street analysts forecast RPTX's earnings for 2025 to be -$105,083,937, with the lowest RPTX earnings forecast at -$119,667,014, and the highest RPTX earnings forecast at -$90,500,860. On average, 1 Wall Street analyst forecast RPTX's earnings for 2026 to be -$73,344,299, with the lowest RPTX earnings forecast at -$73,344,299, and the highest RPTX earnings forecast at -$73,344,299.
In 2027, RPTX is forecast to generate -$41,175,747 in earnings, with the lowest earnings forecast at -$41,175,747 and the highest earnings forecast at -$41,175,747.